Beyond Air (XAIR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Beyond Air faces a critical risk regarding its ability to maintain the listing of
Beyond Air (XAIR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Beyond Air faces a critical risk regarding its ability to maintain the listing of
Beyond Air ( ($XAIR) ) has released its Q2 earnings. Here is a breakdown of the information Beyond Air presented to its investors. Beyond Air, Inc., a commercial-stage medical device
Laidlaw lowered the firm’s price target on Beyond Air (XAIR) to $5 from $8 and keeps a Buy rating on the shares following the fiscal Q2 report. The firm says